EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis



Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis



Journal of Bone and Mineral Research 16(10): 1871-1878



The objective of this study was to compare efficacy and safety of continuous versus intermittent oral dosing of ibandronate. Two hundred forty women aged 55-75 years with postmenopausal osteoporosis were randomized to active treatment or placebo. Similar total doses of ibandronate were provided by treatment regimens with either continuous 2.5 mg of ibandronate daily (n = 81) or intermittent 20 mg of ibandronate every other day for the first 24 days, followed by 9 weeks without active drug (n = 78). The placebo group (total, n = 81) was crossed over after 12 months to receive either continuous (n = 37) or intermittent ibandronate (n = 35). By 24 months, bone mineral density (BMD) had increased significantly relative to baseline in both active treatment groups. The continuous and intermittent groups showed statistically equivalent increases in lumbar spine BMD of +5.64% (+/-0.53) and +5.54% (+/-0.53) and in total hip of +3.35% (+/-0.40) and +3.41% (+/-0.40), respectively (per protocol population). Biochemical markers of bone turnover decreased significantly in both treatment groups. The level of marker suppression was similar, although the intermittent group displayed, as expected, more fluctuation over the treatment period. The frequency of adverse events was similar in the treatment groups. In conclusion, the intermittent and continuous regimens showed equivalent changes in BMD and bone turnover. These results confirm previous preclinical findings indicating that the efficacy of ibandronate depends on the total oral dose given rather than on the dosing schedule. This supports development of new flexible dosing regimens targeted to minimize the frequency of dosing, which are expected to improve convenience and lead to enhanced long-term patient compliance.

(PDF emailed within 0-6 h: $19.90)

Accession: 010778292

Download citation: RISBibTeXText

PMID: 11585352

DOI: 10.1359/jbmr.2001.16.10.1871



Related references

Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis. Calcified Tissue International 72(4): 402, April, 2003

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporosis International 15(3): 231-237, 2004

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. Journal of Infectious Diseases 158(1): 7-12, 1988

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clinical Therapeutics 28(4): 475-490, 2006

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporosis International 15(6): 423-433, 2004

A double-blind comparison of once-daily dosing of aminoglycosides versus twice-daily dosing. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 22, 1995

Comparison of serum concentrations with daily cefonicid dosing versus alternate day dosing plus probenecid. Clinical Pharmacology & Therapeutics 41(2): 195, 1987

Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. Drugs in R&d: -, 2018

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporosis International 20(11): 1895-1902, 2011

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Efficacy of escalating to daily interferon dosing in patients who do not respond to intermittent dosing regimens. Hepatology 24(4 PART 2): 400A, 1996

Once-a-week alendronate for postmenopausal osteoporosis is as effective as once-daily dosing. Geriatrics 56(1): 19-19, 2001

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clinical Infectious Diseases 24(5): 796-809, 1997

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 138(4): 1286-96, 1296.E1-3, 2010

Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clinical Trials 9(2): 73-82, 2008